Every 424B that Spyre Therapeutics, Inc. (SYRE) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow SYRE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SYRE filings page.
Spyre Therapeutics, Inc. (SYRE) is offering 4,117,648 shares of common stock at $85.00 per share, for a total public offering price of $350,000,080.00. Estimated net proceeds are approximately $328.7 million, or approximately $378.0 million if the underwriters exercise in full their option to buy up to 617,647 additional shares. Spyre intends to use proceeds to advance its gastroenterology, rheumatology and dermatology programs, including clinical trials, manufacturing and Phase 3 readiness, and to advance SPY072 into late-stage development for HS. It also intends to use a portion for infrastructure and may use a portion for in-licensing, acquisitions or investments; remaining proceeds are for research and development, working capital and general corporate purposes.
As of June 30, 2026, Spyre had approximately $1.1 billion in cash, cash equivalents and marketable securities. Based on current business plans, it believes existing funds and offering proceeds will fund planned operations into the second half of 2029. The company estimates immediate dilution to offering purchasers of $71.51 per share, with pro forma as-adjusted net tangible book value of $13.49 per share. The underwriters expect share delivery on or about October 7, 2026.
Spyre Therapeutics, Inc. (SYRE) is conducting a preliminary primary offering of common stock, with net proceeds to the company after underwriting discounts, commissions and estimated offering expenses. Underwriters may purchase additional shares from Spyre under an option exercisable within 30 days at the public offering price, less underwriting discounts and commissions. Spyre intends to use net proceeds to advance its Gastroenterology, Rheumatology and Dermatology programs—including preclinical studies, clinical trials, manufacturing and Phase 3 readiness—and to advance SPY072 into late-stage development for hidradenitis suppurativa. It may also allocate proceeds to infrastructure, in-licensing, acquisitions or investments, research and development, working capital and general corporate purposes.
Spyre reported approximately $1.1 billion in cash, cash equivalents and marketable securities as of June 30, 2026, and anticipates this balance will fund operating expenses and capital expenditures into the second half of 2029. Spyre also states that purchasers will incur immediate and substantial dilution, with potential further dilution from future equity or convertible-security issuances.
Spyre Therapeutics, Inc. is offering 6,500,000 shares of its common stock at a public offering price of $62.00 per share, representing a total public offering price of $403,000,000. The company expects to receive approximately $378.8M in proceeds before expenses and has granted the underwriters a 30-day option to purchase up to 975,000 additional shares. The underwriters expect to deliver the shares on or about April 16, 2026. The prospectus supplement states the company had approximately $741M of cash, cash equivalents and marketable securities as of March 31, 2026, and that net proceeds will fund its IBD and rheumatic disease antibody programs, development activities, manufacturing and general corporate purposes.
Spyre Therapeutics, Inc. is proposing a primary offering of $300,000,000 of common stock on the Nasdaq Global Select Market (symbol SYRE), with underwriters holding a 30-day option to purchase additional shares. The prospectus states a last reported sale price of $51.29 per share on April 10, 2026.
The company reported positive 12-week SKYLINE Part A induction topline results for SPY001 (change in RHI: -9.2, p<0.0001), said Part A recruitment is closed and Part B enrollment is open, and expects further readouts mid-2026 and in 2027. Spyre also reported approximately $741 million of cash, cash equivalents and marketable securities as of March 31, 2026 (preliminary).